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Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), 
spreads rapidly and has been announced a pandemic by the World Health Organization (WHO). COVID-19 espe-
cially affects cardiovascular system, mostly by leading to the dysfunction of endothelium and its consequences. On 
the other hand, patients with a history of chronic disease are believed to have a more severe course of COVID-19. 
Furthermore, apart from an undoubted influence on morbidity and mortality, COVID-19 results in changes in 
many aspects of human life. It is worth noting that pandemic will also affect people who did not suffer from disease. 
Nevertheless, due to constantly elevated stress level, COVID-19 may have influence on mental health. Paradoxically, 
in dealing with stress and COVID-related problems, faith and religiosity can play a leading role. In this review, at-
tention was paid not only to possible cardiac complications of infection but also to the impact of the pandemic on 
psychological and spiritual effects of the pandemic. 
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Introduction
Coronavirus disease 2019 (COVID-19), announced 
by the World Health Organization (WHO) as a pan-
demic, undoubtedly will influence worldwide medi-
cine and health care system. Severe acute respira-
tory syndrome coronavirus (SARS-CoV-2) causing 
COVID-19, may manifest in multiple ways: from 
asymptomatic, through mild fever, dry cough to se-
vere pneumonia requiring a hospitalization in an 
intensive care unit (ICU) and necessity of intuba-
tion. Such a variety of symptoms certainly does not 
make the diagnosis simple, and may even delay ap-
propriate diagnosis, leading to treatment delay and 
complications.
By the beginning of November, almost 46 million 
people worldwide were tested positive for SARS-
CoV-2, of whom up to 13% have died [1]. Originat-
ing in the Chinese town of Wuhan single-stranded 
ribonucleic acid (RNA) virus may affect both short- 
and long-term outcomes, including cardiovascular 
ones [2]. The present analysis reveals a potential 
arterial hypertension 2020, vol. 24, no. 4
144 www.ah.viamedica.pl
relationship between SARS-CoV-2 infection and 
chronic diseases.  
Origins of COVID-19 complications 
SARS-CoV-2 is a pathogen with high affinity to 
lungs endothelial cells. An essential part of enter-
ing virus into the human host cells is angiotensin-
converting enzyme 2 (ACE2) receptor and trans-
membrane protease serin receptor 2 (TMPRSS2) 
[2]. Immune system stimulation results in a cytokine 
storm with interleukin secretion, macrophage activa-
tion and finally, endothelial cells dysfunction. The 
endothelium is essential in appropriate hemostasis. 
However, activated endothelial cells play a negative 
role in thrombogenesis.
The endothelium is the most affected in SARS-
CoV-2 infection. The study conducted by Acker-
mann et al. on a small group of post-mortem lungs 
examination of seven patients deceased due to 
COVID-19 revealed significant lesions in endothe-
lium [3]. Similar observations were provided by nu-
merous studies from a dozen countries [4]. Based on 
these observations, SARS-CoV-2 was announced vas-
cular disease. Therefore, it is worth noting that most 
long-term COVID-19 complications result from 
chronic inflammation leading to the dysfunction of 
the endothelium. Furthermore, these mechanisms 
are responsible for molecular mimicry, activation of 
autoimmune processes, ultimately manifesting in left 
ventricle impairment.
Possible complications of COVID-19 
infection
Although it has not been long since the first diag-
nosed case, reports of possible cardiovascular out-
comes are available. Based on data available from the 
previous SARS epidemic in 2003, it can be assumed 
that hypotension and arrhythmias, including sud-
den cardiac death, are mostly described in patients 
suffering from SARS infections without the previous 
cardiovascular disease [5]. Taking into consideration 
pro-coagulation conditions during infection, the risk 
of pulmonary embolism (PE) increases significantly. 
A study conducted in a group of 689 patients hospi-
talized in an intensive care unit at the beginning of 
pandemic revealed that 7.5% developed PE, despite 
almost two-thirds of them were receiving anticoagu-
lation treatment [6]. In Dutch hospitals, this per-
centage was even higher, and PE complicated 31% 
cases of severe COVID-19 [7]. Another observa-
tional study showed that new-onset atrial fibrillation 
(AF) worsened outcome in COVID-19, especially 
by leading to the combined endpoint of thrombosis 
and death [8]. 
Another important cardiac complication which 
may be developed is myocarditis, probably as an 
effect of chronic inflammation, resulting in infil-
tration of myocardium by cytokines [9]. Moreover, 
COVID-19 associated pneumonia also contributes 
to myocardial damage, and thus, to acute heart fail-
ure and in long-term observation, chronic heart fail-
ure with cardiomyopathy. Further diagnostics with 
cardiac magnetic resonance is needed in order to 
assess early myocardial damage. It is worth emphasiz-
ing that routine cardiac diagnostics, including ECG 
or echocardiography, do not reveal subclinical heart 
injury. Also, laboratory markers, such as elevated 
high-sensitivity cardiac troponin (hs-cTn) level, are 
unspecific in predicting side effects of COVID-19. 
Moreover, patients with acute infection are at 
higher risk of developing cardiac complications, 
especially myocardial infarction and mortality [2]. 
Even though these observations were made for in-
fluenza, it is highly probable that similar conclu-
sions will be taken in long-term assessment of SARS-
CoV-2 pandemic. Not surprisingly, another potential 
cardiac complication in the course of SARS-CoV-2 
infection seems to be takotsubo syndrome (TTS), 
resulting from emotional and physical stress or phar-
macotherapy [10, 11]. 
Impact of chronic disease  
on the SARS-CoV-2 infection’s course
Undoubtedly patients with typical cardiovascular 
risk factors, including male sex, advanced age, obe-
sity, with concomitant diabetes and hypertension 
have a greater risk of mortality due to COVID-19. 
One of the earliest published analyses from Wuhan 
showed that almost one-third of 138 patients hos-
pitalized due to SARS-CoV-2-acquired pneumonia 
were previously diagnosed with hypertension, and 
14.5% had concomitant cardiovascular disease [12]. 
Another meta-analysis confirmed that patients with 
a severe course of SARS-CoV-2 were more frequently 
diagnosed with previous hypertension, chronic heart 
failure, as well as chronic kidney disease, diabetes, 
chronic lung disease and malignancy [13]. Role of 
co-existing cardiovascular disease and greater risk 
of mortality from SARS-CoV-2 was established in 
a meta-analysis of more than 65 thousand people 
[14]. Similarly, a large meta-analysis of 41 studies 
confirmed 3.42 times higher risk of death in co-
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existing cardiovascular disease [15]. Retrospective 
American study analyzed 6,439 patients hospitalized 
due to COVID-19 presented that patients previously 
diagnosed with heart failure had poorer outcome, 
stayed in the hospital longer and had a higher risk of 
mechanical ventilation and mortality, regardless of 
left ventricle ejection fraction [16]. Zhang et al. con-
firmed that inappropriate lipid parameters described 
as increased triglycerides/high-density lipoprotein 
cholesterol (TG/HDL-C) ratio had been considered 
as risk factors of myocardial injury, heart failure, 
COVID-19 severity and fatal outcome [17].
Conditions linked to a higher risk of severe 
COVID-19 course are listed in Table 1.
Other aspects of SARS-CoV-2 infection
COVID-19 has an impact not only on the cardiovas-
cular system but also on physical aspects of human’s 
life. Zandifar et al. had researched 106 patients with 
mild, uncomplicated SARS-CoV-2 infection. The 
study aimed to establish a prevalence of depression, 
anxiety and stress among hospitalized patients. Final-
ly, almost every participant had symptoms of depres-
sion, anxiety and was stressed, which was evaluated 
on the basis of the appropriate questionnaires [18]. It 
should be emphasized that stress level also increases 
in healthy people, who have been affected by the 
socio-economic consequences of the pandemic. The 
prospect of losing a job, a brief period of introducing 
governments’ restrictions and, consequently, a short 
time to prepare for the situation have an impact on 
mental health and physical well-being. Spanish study 
involved 21 207 respondents and presented an as-
sociation between unstable situation and depressive 
disorders, ranging from 40.9% to 74.4% [19]. In-
flammatory reaction, secretion of cytokines, includ-
ing C-reactive protein (CRP), was strongly associated 
with an increased level of depressive disorders among 
COVID-19 patient [20].
For millennia religion played a key role in dealing 
with threats, including global crises. Collaboration 
between religion, government and science has been 
underlined in SARS-CoV-2 pandemic. Such activi-
ties increase the sense of security and reduce the level 
of stress, which helps in faster recovery from the 
disease [21]. Spirituality also played a fundamental 
role in the end-stage of the disease. Spiritual support 
provided by chaplains during palliative care was rec-
ommended as a part of treatment by the European 
Respiratory Society [22]. This statement was strongly 
supported by American health care providers [23]. 
Results from cross-sectional Brazilian study revealed 
that people taking part in private religious activities 
better dealt with social isolation were less stressed 
and had a lower level of sadness [24]. Nevertheless, 
it is worth to note that many chaplains, especially in 
Italy in the critical period of the pandemic, sacrificed 
their lives, repeatedly exposed to infection by giving 
spiritual assistance both to patients in the end-stage 
of disease and their families [25].
The last aspect of the pandemic worth noticing is 
its impact on science and evidence based medicine. 
The coronavirus disease-2019 (COVID-19) pan-
demic has profoundly changed clinical care and re-
search, including the conduct of clinical trials which 
are now hard to conduct and require additional mea-
sures. [26] On the other hand, trials of potential 
COVID-19 drugs and vaccines are being conducted 
faster than ever. Recently, on the American scientific 
arena a series of meetings of scientists and represen-
tatives of the industry, were convened to address 
the challenges caused by the COVID-19 pandemic. 
[26]. A series of recommendations were issued which 
will probably change the science as we know it.
Conclusion
COVID-19 pandemic will undoubtedly affect each 
of us and change many parts of our lives. However, 
the impact of the infection on physical condition is 
obvious, and we should also be aware of the long-
Table 1. Factors associated with worsened COVID-19 course
Clinical conditions  
with a definitive association 
with an increased risk  
of severe course of COVID-19
Clinical conditions  
with a probable association 
with an increased risk  
of severe course of COVID-19
Cancer Asthma (moderate to severe)
Chronic kidney disease Other cardiovascular diseases
Chronic obstructive pulmonary 
disease Cystic fibrosis
Cardiovascular diseases,  
such as: chronic heart failure, 
chronic coronary syndrome, 
cardiomyopathies
Arterial hypertension
Immunodeficiency (e.g. after 
organ transplantation) 
Neurological diseases  
such as dementia
Obesity Liver diseases
Sickle cell disease Overweight
Smoking Pregnancy
Diabetes mellitus type 2 Pulmonary fibrosis
Diabetes mellitus type 1
Thallasemias
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term effects of the pandemic on physical and men-
tal health. The summary of the probable impact of 
COVID-19 on the cardiovascular events rate — the 
most frequent cause of mortality and morbidity — is 
shown in Table 2. Nevertheless, it seems that reli-
giosity and spirituality may have one of the largest 
influences on mental well-being and help in recovery 
from disease. Further analysis is still needed to prove 
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Nonfatal CV Events Fatal CV Events
Reduction in event 
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Fear of hospitalization and contracting COVID-19 in the inpatient  
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COPD — chronic pulmonary obstructive disease; COVID-19 — coronavirus disease-2019; CV — cardiovascular; HF — heart failure
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